UCB Biopharma SPRL
UCB, founded in 1928, is a global biopharmaceutical company with 8 700 people in approximately 40 countries. UCB is focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Key staff involved in EBiSC
Patrik Foerch (Sr. Director) – Patrik Foerch obtained his PhD from EMBL Heidelberg. Patrik joined UCB Neuroscience in Belgium in 2006 and is currently Head of Molecular Biology and Gene Expression.
Frank Atienzar (Associate Director) – Franck Atienzar obtained his PhD in 2000 at the University of Plymouth (UK). Franck joined Non-Clinical Development (UCB) in 2002 and is currently Head of in silico and in vitro toxicology.
Alison Maloney (Director) – Alison Maloney obtained her PhD in 2001 at the Institute of Cancer Research, London. She joined UCB in Slough in 2003 and is currently Director, Cellular Sciences (Mode of Action) group.
More information: www.ucb.com »